MINERALYS THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $2.62M, a 142.45% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $4.05M, a 3196.75% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $6.62M, a 16460.00% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.08M, a 1898.15% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $12.79M, a 4205.05% increase from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $297.00K, a 53.09% increase from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $194.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $2.62M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $4.05M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $12.79M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $6.62M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $1.08M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $123.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $297.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $40.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $54.00K 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $149.00K 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $194.00K 10-K · filed 2025-02-12 | |
| 2023-09-30 | $184.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |